{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:06:54Z","timestamp":1777579614533,"version":"3.51.4"},"reference-count":49,"publisher":"Becaris Publishing Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Current Parkinson\u2019s disease (PD) research evaluates patients with early and severe PD, but often overlooks patients with intermediate PD. This study aims to quantify unmet treatment needs, disease burden and healthcare resource utilization among patients with PD within different Hoehn and Yahr stage groups in the US.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Data were drawn from the Adelphi Parkinson\u2019s Disease Specific Programme\u2122, a cross-sectional survey of physicians and their patients in the US from September 2021 to April 2022. Patients were staged as early (Hoehn and Yahr stage 1\u20132), intermediate (stage 2.5\u20133) or severe (stage 4\u20135) PD. Analyses compared PD stages, focusing on the intermediate group.\n                    <jats:bold>Results:<\/jats:bold>\n                    Ninety-five physicians provided data for 1251 patients; 47.4%, 40.4%, and 12.2% were early-, intermediate-, and severe-stage PD, respectively. Mean age was 65.1, 71.8, and 77.8 years and mean time since diagnosis was 2.5, 5.1, and 7.7 years (p &lt; 0.001) across early, intermediate, and severe groups, respectively. The mean number of products used in current regimen was 1.1 for early, 1.9 for intermediate and 2.4 for severe groups. The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p &lt; 0.001), e.g., slowing disease progression, providing neuroprotection. Incidence rate ratios were increased for the intermediate versus early group for number (in previous 12 months) of healthcare professionals involved in patients\u2019 PD management (incidence rate ratios 1.1), healthcare professional consultations (1.4), emergency room visits (3.8) and rehabilitation admissions (6.8). Patient-reported quality of life was significantly poorer in the intermediate versus early group.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This real-world analysis found significant increases in disease burden and healthcare resource utilization for patients with intermediate versus early PD. More effective intervention of patients at intermediate-stage PD may improve symptom control and decrease the PD burden for patients and the healthcare system.\n                  <\/jats:p>","DOI":"10.57264\/cer-2024-0186","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:44:59Z","timestamp":1758620699000},"source":"Crossref","is-referenced-by-count":1,"title":["Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson\u2019s disease: results from a real-world study"],"prefix":"10.57264","volume":"14","author":[{"given":"Malgorzata","family":"Ciepielewska","sequence":"first","affiliation":[{"name":"Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ 07310, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie","family":"Jones","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Mill, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Mill, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Walker","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Mill, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"LeBrocq","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Mill, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Weatherby","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Mill, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"9996","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia LV","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson's disease. Lancet 386(9996), 896\u2013912 (2015).","journal-title":"Lancet"},{"key":"e_1_3_10_4_2","volume-title":"Parkinson's Disease: Pathogenesis and Clinical Aspects","author":"Kouli A","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL. Chapter 1: Parkinson's disease: etiology, neuropathology, and pathogenesis. In: Parkinson's Disease: Pathogenesis and Clinical Aspects. Stoker TB, Greenland JC (Eds). Codon Publications, Australia (2018)."},{"key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou Z","year":"2021","unstructured":"Ou Z, Pan J, Tang S Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories from 1990 to 2019. Front. Public Health 9, 776847 (2021).","journal-title":"Front. Public Health"},{"issue":"2","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","article-title":"Burden of neurological disorders across the US from 1990\u20132017: a Global Burden of Disease study","volume":"78","author":"US Neurological Disorders Collaborators","year":"2021","unstructured":"US Neurological Disorders Collaborators; Feigin VL, Vos T, Alahdab F Burden of neurological disorders across the US from 1990\u20132017: a Global Burden of Disease study. JAMA Neurol. 78(2), 165\u2013176 (2021).","journal-title":"JAMA Neurol."},{"issue":"1","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.28265","article-title":"Burden of Parkinson's disease by severity: health care costs in the U.S. medicare population","volume":"36","author":"Dahodwala N","year":"2021","unstructured":"Dahodwala N, Li P, Jahnke J Burden of Parkinson's disease by severity: health care costs in the U.S. medicare population. Mov. Disord. 36(1), 133\u2013142 (2021).","journal-title":"Mov. Disord."},{"key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson's disease in the U.S","volume":"6","author":"Yang W","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C Current and projected future economic burden of Parkinson's disease in the U.S. NPJ. Parkinsons Dis. 6, 15 (2020).","journal-title":"NPJ. Parkinsons Dis."},{"key":"e_1_3_10_9_2","volume-title":"Parkinson disease. A public health approach. Technical brief","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Parkinson disease. A public health approach. Technical brief. World Health Organization, Switzerland (2022)."},{"issue":"1","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino R","year":"2020","unstructured":"Balestrino R, Schapira AHV. Parkinson disease. Eur. J. Neurol. 27(1), 27\u201342 (2020).","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa E","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 20(5), 385\u2013397 (2021).","journal-title":"Lancet Neurol."},{"issue":"6","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1474-4422(16)00116-2","article-title":"The new definition and diagnostic criteria of Parkinson's disease","volume":"15","author":"Postuma RB","year":"2016","unstructured":"Postuma RB, Berg D, Adler CH The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 15(6), 546\u2013548 (2016).","journal-title":"Lancet Neurol."},{"issue":"8","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes OB","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J. Neural. Transm. (Vienna) 124(8), 901\u2013905 (2017).","journal-title":"J. Neural. Transm. (Vienna)"},{"issue":"5","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","article-title":"Biomarkers for Parkinson's disease: recent advancement","volume":"33","author":"Lotankar S","year":"2017","unstructured":"Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson's disease: recent advancement. Neurosci. Bull. 33(5), 585\u2013597 (2017).","journal-title":"Neurosci. Bull."},{"key":"e_1_3_10_15_2","volume-title":"Parkinson's Disease: Pathogenesis and Clinical Aspects","author":"Zahoor I","year":"2018","unstructured":"Zahoor I, Shafi A, Haq E. Chapter 7: pharmacological treatment of Parkinson's disease. In: Parkinson's Disease: Pathogenesis and Clinical Aspects. Stoker TB, Greenland JC (Eds). Codon Publications, Australia (2018)."},{"issue":"11","key":"e_1_3_10_16_2","first-page":"679","article-title":"Parkinson disease","volume":"102","author":"Halli-Tierney AD","year":"2020","unstructured":"Halli-Tierney AD, Luker J, Carroll DG. Parkinson disease. Am. Fam. Physician 102(11), 679\u2013691 (2020).","journal-title":"Am. Fam. Physician"},{"issue":"1","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","article-title":"Unmet needs in Parkinson disease: motor and non-motor","volume":"80","author":"LeWitt PA","year":"2020","unstructured":"LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: motor and non-motor. Parkinsonism Relat. Disord. 80(Suppl. 1), S7\u2013S12 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","article-title":"Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach","volume":"23","author":"Lees A","year":"2023","unstructured":"Lees A, Tolosa E, Stocchi F Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev. Neurother. 23(1), 15\u201324 (2023).","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41398-018-0162-2","article-title":"NMDA antagonists for treating the non-motor symptoms in Parkinson's disease","volume":"8","author":"Vanle B","year":"2018","unstructured":"Vanle B, Olcott W, Jimenez J NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. Transl. Psychiatry 8(1), 117 (2018).","journal-title":"Transl. Psychiatry"},{"key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"109027","DOI":"10.1016\/j.neuropharm.2022.109027","article-title":"Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease","volume":"210","author":"Cenci MA","year":"2022","unstructured":"Cenci MA, Skovg\u00e5rd K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology 210, 109027 (2022).","journal-title":"Neuropharmacology"},{"key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.28339","article-title":"Estimating the effect of early treatment initiation in Parkinson's disease using observational data","volume":"36","author":"van den Heuvel L","year":"2021","unstructured":"van den Heuvel L, Evers LJW, Meinders MJ Estimating the effect of early treatment initiation in Parkinson's disease using observational data. Mov. Disord. 36, 407\u2013414 (2021).","journal-title":"Mov. Disord."},{"issue":"5","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano G","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J Trial of prasinezumab in early-stage Parkinson's disease. N. Engl. J. Med. 387(5), 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_10_23_2","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1212\/WNL.0000000000009946","article-title":"Deep brain stimulation in early-stage Parkinson disease: five-year outcomes","volume":"95","author":"Hacker ML","year":"2020","unstructured":"Hacker ML, Turchan M, Heusinkveld LE Deep brain stimulation in early-stage Parkinson disease: five-year outcomes. Neurology 95(4), e393\u2013e401 (2020).","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.17925\/ENR.2019.14.1.28","article-title":"Societal burden and persisting unmet needs of Parkinson's disease","volume":"14","author":"Chaudhuri KR","year":"2019","unstructured":"Chaudhuri KR, Titova N. Societal burden and persisting unmet needs of Parkinson's disease. Eur. Neurol. Rev. 14(1), 28\u201335 (2019).","journal-title":"Eur. Neurol. Rev."},{"issue":"9","key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","article-title":"Movement disorder society task force on rating scales for Parkinson's Disease. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations","volume":"19","author":"Goetz CG","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O Movement disorder society task force on rating scales for Parkinson's Disease. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 19(9), 1020\u20131028 (2004).","journal-title":"Mov. Disord."},{"key":"e_1_3_10_26_2","doi-asserted-by":"crossref","first-page":"p4","DOI":"10.1007\/978-1-60327-426-5_2","volume-title":"Movement Disorders: A Video Atlas","author":"Bhidayasiri R","year":"2012","unstructured":"Bhidayasiri R, Tarsy D. Parkinson's disease: Hoehn and Yahr scale. In: Movement Disorders: A Video Atlas. Humana Totowa, USA, p4\u20135 (2012)."},{"issue":"11","key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes \u2013 a means to understand","volume":"24","author":"Anderson P","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes \u2013 a means to understand. Curr. Med. Res. Opin. 24(11), 3063\u20133072 (2008).","journal-title":"Curr. Med. Res. Opin."},{"issue":"12","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes","volume":"39","author":"Anderson P","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr. Med. Res. Opin. 39(12), 1707\u20131715 (2023).","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme","volume":"6","author":"Babineaux SM","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open 6(8), e010352 (2016).","journal-title":"BMJ Open"},{"key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with Type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins V","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A Trends in medication use in patients with Type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab. Syndr. Obes. 9, 371\u2013380 (2016).","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"3","key":"e_1_3_10_31_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02260863","article-title":"The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease","volume":"4","author":"Peto V","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual. Life Res. 4(3), 241\u2013248 (1995).","journal-title":"Qual. Life Res."},{"issue":"3","key":"e_1_3_10_32_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16(3), 199\u2013208 (1990).","journal-title":"Health Policy"},{"key":"e_1_3_10_33_2","volume-title":"EQ-5D-5L User Guide.v3 2019","author":"EuroQol Research Foundation","year":"2021","unstructured":"EuroQol Research Foundation. EQ-5D-5L User Guide.v3 2019. EuroQol Research Foundation, Rotterdam, The Netherlands (2021).Available from: https:\/\/euroqol.org\/publications\/user-guides\/"},{"issue":"5","key":"e_1_3_10_34_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a Work Productivity and Activity Impairment instrument","volume":"4","author":"Reilly MC","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a Work Productivity and Activity Impairment instrument. Pharmacoeconomics 4(5), 353\u2013365 (1993).","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"e_1_3_10_35_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/geront\/20.6.649","article-title":"Relatives of the impaired elderly: correlates of feelings of burden","volume":"20","author":"Zarit SH","year":"1980","unstructured":"Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 20(6), 649\u2013655 (1980).","journal-title":"Gerontologist"},{"key":"e_1_3_10_36_2","unstructured":"European Pharmaceutical Market Research Association (EPHMRA). Code of Conduct. (2020). Available from: https:\/\/www.ephmra.org\/media\/4857\/ephmra-2020-code-of-conduct-final.pdf"},{"key":"e_1_3_10_37_2","unstructured":"US Department of Health and Human Services. Summary of the HIPAA Privacy Rule. (2003). Available from: http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf"},{"key":"e_1_3_10_38_2","unstructured":"Health Information Technology (HITECH). Health Information Technology Act. (2009). Available from: https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf"},{"issue":"2","key":"e_1_3_10_39_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","article-title":"Early detection of wearing off in Parkinson disease: the DEEP study","volume":"20","author":"Stocchi F","year":"2014","unstructured":"Stocchi F, Antonini A, Barone P Early detection of wearing off in Parkinson disease: the DEEP study. Parkinsonism Relat. Disord. 20(2), 204\u2013211 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"8","key":"e_1_3_10_40_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00228-015-1881-4","article-title":"Trends in inpatient antiparkinson drug use in the USA, 2001\u20132012","volume":"71","author":"Crispo JA","year":"2015","unstructured":"Crispo JA, Fortin Y, Thibault DP Trends in inpatient antiparkinson drug use in the USA, 2001\u20132012. Eur. J. Clin. Pharmacol. 71(8), 1011\u20131019 (2015).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"e_1_3_10_41_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneurol.2009.287","article-title":"Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease","volume":"67","author":"Brodsky MA","year":"2010","unstructured":"Brodsky MA, Park BS, Nutt JG. Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Arch. Neurol. 67(1), 27\u201332 (2010).","journal-title":"Arch. Neurol."},{"issue":"2","key":"e_1_3_10_42_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","article-title":"Catechol-O-methyltransferase inhibitors in Parkinson's disease","volume":"75","author":"M\u00fcller T","year":"2015","unstructured":"M\u00fcller T. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Drugs 75(2), 157\u2013174 (2015).","journal-title":"Drugs"},{"issue":"18","key":"e_1_3_10_43_2","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.3390\/ijms20184391","article-title":"Roles of glutamate receptors in Parkinson's disease","volume":"20","author":"Zhang Z","year":"2019","unstructured":"Zhang Z, Zhang S, Fu P Roles of glutamate receptors in Parkinson's disease. Int. J. Mol. Sci. 20(18), 4391 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"e_1_3_10_44_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00044011-200727030-00004","article-title":"Treatment of Parkinson's disease: a survey of patients and neurologists","volume":"27","author":"Fargel M","year":"2007","unstructured":"Fargel M, Grobe B, Oesterle E, Hastedt C, Rupp M. Treatment of Parkinson's disease: a survey of patients and neurologists. Clin. Drug Investig. 27(3), 207\u2013218 (2007).","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"e_1_3_10_45_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-0037-1602423","article-title":"Motor complications of dopaminergic medications in Parkinson's disease","volume":"37","author":"Freitas ME","year":"2017","unstructured":"Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson's disease. Semin. Neurol. 37(2), 147\u2013157 (2017).","journal-title":"Semin. Neurol."},{"issue":"1","key":"e_1_3_10_46_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/brainsci12010111","article-title":"Caregiver burden and quality of life in late stage Parkinson's disease","volume":"12","author":"Rosqvist K","year":"2022","unstructured":"Rosqvist K, Schrag A, Odin P. The CLaSP Consortium. Caregiver burden and quality of life in late stage Parkinson's disease. Brain Sci. 12(1), 111 (2022).","journal-title":"Brain Sci."},{"issue":"3","key":"e_1_3_10_47_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/cns.13549","article-title":"Quality of life in Parkinson's disease: a systematic review and meta-analysis of comparative studies","volume":"27","author":"Zhao N","year":"2021","unstructured":"Zhao N, Yang Y, Zhang L Quality of life in Parkinson's disease: a systematic review and meta-analysis of comparative studies. CNS Neurosci. Ther. 27(3), 270\u2013279 (2021).","journal-title":"CNS Neurosci. Ther."},{"issue":"6","key":"e_1_3_10_48_2","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1212\/WNL.0000000000012290","article-title":"Health care resource utilization associated with Parkinson disease among Medicare beneficiaries","volume":"97","author":"Gandhi AB","year":"2021","unstructured":"Gandhi AB, Onukwugha E, Albarmawi H Health care resource utilization associated with Parkinson disease among Medicare beneficiaries. Neurology 97(6), e597\u2013e607 (2021).","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_10_49_2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/13696998.2021.1913009","article-title":"Real-world assessment of \u201cOFF\u201d episode-related healthcare resource utilization among patients with Parkinson's disease in the United States","volume":"24","author":"Thach A","year":"2021","unstructured":"Thach A, Jones E, Pappert E, Pike J, Wright J, Gillespie A. Real-world assessment of \u201cOFF\u201d episode-related healthcare resource utilization among patients with Parkinson's disease in the United States. J. Med. Econ. 24(1), 540\u2013549 (2021).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_10_50_2","first-page":"S142","article-title":"Real-world healthcare resource utilization in patients with Parkinson's disease and motor fluctuations","volume":"35","author":"Serbin M","year":"2022","unstructured":"Serbin M, Odak S, Macahilig C Real-world healthcare resource utilization in patients with Parkinson's disease and motor fluctuations. Mov. Disord. 35(Suppl.1), S142 (2022). Available at: https:\/\/www.mdsabstracts.org\/abstract\/real-world-healthcare-resource-utilization-in-patients-with-parkinsons-disease-and-motor-fluctuations\/","journal-title":"Mov. Disord."},{"issue":"9","key":"e_1_3_10_51_2","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora LM","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann. Intern. Med. 175(9), 1298\u20131304 (2022).","journal-title":"Ann. Intern. Med."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:14:43Z","timestamp":1761905683000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.57264\/cer-2024-0186"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0186","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"e240186"}}